Eli Lilly and Company (LLY)
Largest Insider Buys in Sector
LLY Stock Price History Chart
LLY Stock Performance
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal …
Insider Activity of Eli Lilly and Company
Over the last 12 months, insiders at Eli Lilly and Company have bought $0 and sold $2.35B worth of Eli Lilly and Company stock.
On average, over the past 5 years, insiders at Eli Lilly and Company have bought $478.61M and sold $5.55B worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 29,992,668 shares for transaction amount of $374.91M was made by Kearny Acquisition Corp (director) on 2022‑11‑30.
List of Insider Buy and Sell Transactions, Eli Lilly and Company
| 2024-11-08 | Sale | SVP, Finance, & CAO | 900 <0.0001% | $803.38 | $723,042 | -1.95% | ||
| 2024-09-03 | Sale | 10 percent owner | 24,084 0.0026% | $966.69 | $23.28M | -5.46% | ||
| 2024-08-27 | Sale | 10 percent owner | 24,552 0.0026% | $968.46 | $23.78M | -5.06% | ||
| 2024-08-26 | Sale | SVP, Finance, & CAO | 750 <0.0001% | $950.00 | $712,500 | -4.67% | ||
| 2024-08-22 | Sale | 10 percent owner | 3,196 0.0003% | $966.33 | $3.09M | -4.81% | ||
| 2024-07-10 | Sale | 10 percent owner | 210,000 0.023% | $939.82 | $197.36M | 0.00% | ||
| 2024-07-08 | Sale | 10 percent owner | 93,593 0.01% | $918.64 | $85.98M | 0.00% | ||
| 2024-07-05 | Sale | 10 percent owner | 52,369 0.0056% | $915.18 | $47.93M | 0.00% | ||
| 2024-07-03 | Sale | 10 percent owner | 8,848 0.0009% | $915.31 | $8.1M | 0.00% | ||
| 2024-07-01 | Sale | 10 percent owner | 58,749 0.0063% | $915.26 | $53.77M | 0.00% | ||
| 2024-06-28 | Sale | 10 percent owner | 1,441 0.0002% | $915.02 | $1.32M | 0.00% | ||
| 2024-06-25 | Sale | 10 percent owner | 188,100 0.0198% | $903.82 | $170.01M | -0.16% | ||
| 2024-06-24 | Sale | 10 percent owner | 17,229 0.0018% | $902.38 | $15.55M | +1.51% | ||
| 2024-06-20 | Sale | 10 percent owner | 9,671 0.0011% | $902.67 | $8.73M | +1.89% | ||
| 2024-06-17 | Sale | 10 percent owner | 194,978 0.021% | $885.91 | $172.73M | +1.84% | ||
| 2024-06-14 | Sale | 10 percent owner | 15,022 0.0016% | $882.47 | $13.26M | +2.60% | ||
| 2024-06-10 | Sale | 10 percent owner | 75,510 0.0079% | $860.78 | $65M | +3.47% | ||
| 2024-06-07 | Sale | 10 percent owner | 139,490 0.0147% | $852.29 | $118.89M | +4.90% | ||
| 2024-06-06 | Sale | 10 percent owner | 179,617 0.0189% | $837.82 | $150.49M | +6.48% | ||
| 2024-06-05 | Sale | 10 percent owner | 20,383 0.0022% | $836.32 | $17.05M | +7.18% |
Insider Historical Profitability
| LECHLEITER JOHN C | former director | 160068 0.0169% | $754.38 | 1 | 2 | <0.0001% |
| Ricks David A | President & CEO | 157405 0.0166% | $754.38 | 1 | 6 | +34.48% |
| Skovronsky Daniel | SVP, CSO, and Pres. LRL | 75818 0.008% | $754.38 | 2 | 0 | +34.08% |
| TAI JACKSON P | 62857 0.0066% | $754.38 | 12 | 0 | +14.08% | |
| White Anne E. | EVP & Pres, Lilly Neuroscience | 57926 0.0061% | $754.38 | 1 | 2 | +34.48% |
Institutional Investor Ownership
| Lilly Endowment | $76.94B | 10.41 | 98.9M | -0.87% | -$676.83M | 100 | |
| The Vanguard Group | $56.59B | 7.65 | 72.75M | +1.58% | +$882.06M | 1.04 | |
| BlackRock | $50.78B | 6.87 | 65.27M | +1.41% | +$706.35M | 1.11 | |
| PNC Financial Services | $40.02B | 5.41 | 51.44M | -0.53% | -$211.04M | 27.99 | |
| State Street | $26.65B | 3.61 | 34.26M | +1.4% | +$366.61M | 1.09 |